Table 3.
Multivariable Cox proportional hazard ratios (HR) for survival.
| All SSc-PAH HR (95% CI, P value) (n = 82) | Female SSc-PAH HR* (95% CI, P value) (n = 65) | |
|---|---|---|
| Uric acid > 6.3 mg/dL | 1.68 (0.89–3.15, 0.11) | 2.40 (1.16–4.98, < 0.05) |
| Adjusted for age, sex, BMI, and: | Adjusted for age, BMI, and: | |
| eGFR (mL/min) | 1.84 (0.93–3.67, 0.08) | 2.61 (1.20–5.71, < 0.05) |
| PAH-specific therapy | 1.98 (1.01–3.87, < 0.05) | 2.76 (1.29–5.92, < 0.01) |
| Monotherapy vs. combo | 2.12 (1.06–4.26, < 0.05) | 2.91 (1.33–6.40, < 0.01) |
| Diuretic therapy | 1.79 (0.90–3.57, 0.09) | 2.52 (1.15–5.51, < 0.05) |
| HTN | 2.20 (1.11–4.37, < 0.05) | 3.30 (1.52–7.17, < 0.01) |
| Diabetes mellitus | 2.00 (1.03–3.91, < 0.05) | 2.84 (1.33–6.07, < 0.01) |
| Coronary disease | 2.30 (1.13–4.68, < 0.05) | 3.34 (1.48–7.53, < 0.01) |
| WHO FC (III, IV vs. I, II) | 1.72 (0.86–3.46, 0.13) | 2.45 (1.11–5.39, < 0.05) |
| 6MWD (m) | 1.89 (0.89–4.03, 0.10) | 2.49 (1.09–5.73, < 0.05) |
| mPAP (mmHg) | 1.59 (0.77–3.29, 0.21) | 2.34 (1.03–5.30, < 0.05) |
| CO (L/min) | 1.85 (0.93–3.67, 0.08) | 2.54 (1.16–5.56, < 0.05) |
| PVR (Wood units) | 1.70 (0.84–3.43, 0.14) | 2.42 (1.09–5.37, < 0.05) |
| DLCO % predicted | 2.01 (0.96–4.19, 0.06) | 2.72 (1.20–6.15, < 0.05) |
| NT-proBNP (pg/dL) | 1.77 (0.76–4.10, 0.19) | 2.63 (1.01–6.85, < 0.05) |
*
Sex is not included as a covariate in multivariable models in the female SSc-PAH subgroup.
BMI, body mass index; eGFR, estimated glomerular filtration rate; WHO FC, World Health Organization functional class; 6MWD, 6-min walk distance; DLCO, diffusing capacity for carbon monoxide; BNP, brain natriuretic peptide.